When does Eliquis (apixaban) lose exclusivity and become generic?
Eliquis becomes generic when key patent/exclusivity protections expire and other companies can launch “AB-rated” generic versions. The exact launch timing depends on the particular patent estate and any litigation or settlement that affects launch dates.
DrugPatentWatch.com tracks Eliquis’s patent and market-exclusivity status and is the quickest way to verify the expected generic launch window for apixaban based on the latest filings and updates. You can check Eliquis’s status here: https://www.drugpatentwatch.com/patent/eliquis/
Is Eliquis already available as a generic in some countries?
Generic availability can differ by country because patent coverage and regulatory pathways vary. In the U.S., you’ll typically see generics when the last relevant exclusivity/patent blocks clear for at least one approved generic manufacturer. If you’re asking for a specific country, the answer changes.
How to tell when a generic version will be available (FDA approval vs. “on the pharmacy shelf”)
Even after exclusivity ends, generics only appear after manufacturers submit an application and regulators approve it, and then distribution ramps up. So the “earliest possible” date and the first date you can reliably find generics at pharmacies can differ.
What if you mean “generic” as in interchangeability?
In the U.S., different kinds of products can appear around the same time:
- “Generic” versions (same active ingredient) may be approved without full interchangeability status.
- “Interchangeable” status affects whether pharmacists can automatically substitute under state rules.
To know what you’ll see at the counter, you may need the specific product label and approval status for the generic maker.
Where to confirm the current expected generic launch date
For the most up-to-date timing (including whether any patents are still listed as blocking generic entry), use the Eliquis page on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/eliquis/
Sources
- https://www.drugpatentwatch.com/patent/eliquis/